Abeona Therapeutics Inc. (ABEO)
Abeona Therapeutics Inc. (ABEO) Stock Price, Analysis & Data
| Bid | 4.47 |
| Market Cap | 341.12M |
| Revenue (ttm) | 25.52M |
| Net Income (ttm) | -62.89M |
| Beta | 1.34 |
| EPS (ttm) | -1.21 |
| PE Ratio (ttm) | n/a |
| Forward PE | -32.65 |
| P/B (ttm) | 2.67 |
| P/S (ttm) | 13.41 |
| Earnings Date | Nov 11, 2026 |
| Ask | 5.99 |
| Volume | 5,445,167 |
| Avg. Volume (20D) | 1,353,837 |
| Open | 6.21 |
| Previous Close | 6.35 |
| Day's Range | 5.82 - 6.29 |
| 52-Week Range | 4.00 - 7.65 |
| Analyst | Strong Buy |
| Price Target | 17 (183.81%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ABEO
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominan...
Financial Performance
In 2025, Abeona Therapeutics's revenue was 5.82M, an increase of undefined% compared to the previous year's 0. Earnings were 71.18M, a decrease of -211.69%.
Financial StatementsAnalyst Forecast
According to 7 analyst ratings, the average rating for ABEO stock is "Strong Buy". The 12-month stock price forecast is 17, which is upside of 183.81% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
